Navigation Links
The Lustgarten Foundation for Pancreatic Cancer Research Launches New Public Service Announcement Featuring 'Last Lecturer' Dr. Randy Pausch
Date:4/17/2008

- Long-form web-based PSA ("Life. Lessons. Legacy.") features Carnegie-Mellon Professor's fight against pancreatic cancer and underscores his call-to-action for additional research into nation's fourth leading

cancer killer - PSA debuts on heels of Lustgarten Foundation's limited online book offer as seen on ABC Primetime with Diane Sawyer, where 5,000 free copies of "The

Last Lecture" were given to the public - Short-form (:30) PSA will air on major cable and television stations,

directing viewers to long-form PSA online

- The Lustgarten Foundation is nation's largest private, non-profit supporter of pancreatic cancer research, providing more than $20 million to

date

BETHPAGE, N.Y., April 17 /PRNewswire/ -- The Lustgarten Foundation for Pancreatic Cancer Research, the nation's largest private foundation dedicated to supporting pancreatic cancer research, announced the debut of a new web- based long-form PSA featuring Dr. Randy Pausch. In the PSA, Dr. Pausch and his wife, Jai, share their thoughts about coping with a diagnosis of pancreatic cancer. Dr. Pausch speaks about the urgent need for additional research into the nation's fourth deadliest cancer and expresses concern that his children may someday face this deadly disease.

Said Dr. Robert Vizza, Lustgarten Foundation President, "Pancreatic cancer is an insidious disease because there is are no reliable tests to detect it early, when the chances for a cure are greatest. The disease is also aggressive and highly resistant to standard treatments."

Said Dr. Randy Pausch, "There have been too few advances in pancreatic cancer and, as a result, patients have limited options. For the sake of generations to come, we need to change the course of this disease. Only by giving the best and brightest scientific minds access to the resources they need will we find better treatments and, ultimately, a cure."

Said Kerri Kaplan, Lustgarten Foundation Executive Director, "The Lustgarten Foundation is committing millions of dollars for promising research precisely because the scientific method is our best hope in the fight against pancreatic cancer. We are proud to have the incredible partnership of the Pausch family, and we thank them for sharing their experience and serving as an inspiration to others."

The PSA is supported by an educational grant from Genentech and OSI Pharmaceuticals. View the PSA online at http://www.lustgarten.org/LUS/Content/CDA/ArticlesDetail.jsp?ContentId=478


'/>"/>
SOURCE The Lustgarten Foundation for Pancreatic Cancer Research
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Lustgarten Foundation Announces $1.25 Million Commitment to Pancreatic Cancer Biomarker Development Project
2. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
3. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
4. International Atomic Energy Agency and National Foundation for Cancer Research Launch Major Initiative to Improve Cancer Prevention and Treatments in Developing Countries
5. Melanoma Research Foundation and Seattle Cancer Care Alliance Host Educational Symposium and Reception for Melanoma Patients, Family Members and Healthcare Providers
6. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
7. The Parkinsons Disease Foundation Commemorates its 50th Anniversary with Special Scientific Symposium on Parkinsons Disease
8. Rutgers physicist earns prestigious Packard Foundation Science and Engineering Fellowship
9. Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award
10. John Timberlake, Valeritas Executive Vice President and General Manager, Named Executive of the Year by the Diabetes Foundation
11. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... CA (PRWEB) , ... October ... ... (https://www.onramp.bio/ ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed ... bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who made ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... pathology, announced today it will be hosting a Webinar titled, “Pathology is going ... Pathology Associates , on digital pathology adoption best practices and how Proscia improves ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh ... orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of ... SBT-100 is able to cross the cell membrane and bind intracellular STAT3 and ...
(Date:10/10/2017)... , Oct. 10, 2017 International research firm Parks ... Strategy, will speak at the TMA 2017 Annual Meeting , October ... trends in the residential home security market and how smart safety and ... Parks ... "The residential ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
Breaking Biology News(10 mins):